NEW YORK – Next-generation sequencing (NGS) or whole-exome sequencing of tumor and normal samples from advanced gastrointestinal (GI) cancer patients helped identify individualized treatment options and pathogenic germline variants associated with cancer risk, according to a study published last week in the Journal of Clinical Oncology: Precision Oncology.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.